As we step into 2025, the biopharmaceutical industry is poised at the intersection of unprecedented innovation and transformative growth. With each yea...
The bioscience economy in the United States has evolved into a critical driver of innovation, economic growth, and soci...
As 2025 unfolds, the pharmaceutical, biopharmaceutical, and biotechnology industries are on the brink of a transformative shift. With mergers and a...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focus...
Professor Narayanan Parameswaran's team at the Department of Physiology at Michigan State University announced the results of a study that s...
Gilead Sciences, Inc. (Nasdaq: GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infe...
Oxford Medical Products is pleased to announce positive topline results from the first randomised controlled trial (RCT) of Sirona, its innova...
Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced the successful first-in-human use of ...
InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. Food and Drug Administration's (FDA) National Cente...
Survey findings from over 8,700 people in 12 countries show that half of those polled have inadequate understanding of HPV, with ne...
Website: www.biopharmaboardroom.com Request Interactions & Submission : editor@biopharmboardroom.com January 2025 Theme: Regulatory and AI...
Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death1 Phase ...
Reported cumulative MMR rate of 44% by 24 weeks, with stable or deepening responses between weeks 12 and 24, continuing to surpass prior Phase 1 trials o...
Roche announced positive topline results from the Phase III REGENCY study, which evaluated Gazyva®/Gazyvaro® (obinutuzumab) in people with active...
© 2024 Biopharma Boardroom. All Rights Reserved.
